Bolt Biotherapeutics Inc. (BOLT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.49 |
Market Cap | 17.84M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.71 |
PE Ratio (ttm) | -0.27 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.53 |
Volume | 84,513 |
Avg. Volume (20D) | 163,153 |
Open | 0.47 |
Previous Close | 0.48 |
Day's Range | 0.46 - 0.48 |
52-Week Range | 0.46 - 1.56 |
Beta | undefined |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...
Analyst Forecast
According to 5 analyst ratings, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 168.24% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription